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Abstract 
Anemia in the elderly (defined as people aged > 65 years) is common and increasing as the population ages. In older 
patients, anemia of any degree contributes significantly to morbidity and mortality and has a significant effect on the 
quality of life. Despite its clinical importance, anemia in the elderly is under-recognized and evidence-based 
guidelines on its management are lacking. Nonetheless, based on the WHO definition, studies have estimated that, in 
people over 65 years, the prevalence of anemia is 12% in those living in the community, 40% in those admitted to 
the hospital, and as high as 47% in nursing home residents. Commonly identified when the elderly are scheduled for 
elective surgical procedures. Anemia is a common condition in surgical patients and is independently associated 
with increased perioperative mortality. What constitutes appropriate evaluation and management for an elderly 
patient with anemia, and when to initiate a referral to a hematologist, are significant issues. In the present review we 
have collected the perspective on the different aspects of evaluation anaemia in the elderly patients and comment on 
the therapeutic management. 
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Introduction 
 
Anaemia is a common nutritional deficiency disorder 
or condition in person lacks enough healthy red blood 
cells to carry adequate oxygen in the entire body's 
tissues. Therefore, it can make people tired and weak 
which mostly affect the global public health in 
developing and developed countries with having 
major consequences for human health and their social 
and economic development.1,2  
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According to WHO (2004) reports, one third of the 
global populations (over 2 billion) are anaemic due to 
imbalance in their nutritious food intake & is now 
recognized as a risk factor for a number of adverse 
outcomes in the elderly, including hospitalization, 
morbidity, and mortality.3 WHO estimates that even 
among the South Asian countries, India has the 
highest prevalence of anaemia. I addition more 
important fact is that about half of the global 
maternal & geriatric deaths are occur due to anaemia 
in South Asian countries like India & it commonly 
affected along with it covers about 80 per cent of the 
death ratio associated with them.4 
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The elderly is an important demographic population 
that is growing rapidlyi in the context of increasing 
prevalence of anemia with age.3 With increasing 
recognition of the importance of anemia in the 
general population, guidelines have been published 
for the detection, evaluation, and management of 
anemia in medical and surgical patients.5,6 However 
for elderly patients, attempts to identify suggested 
hemoglobin levels for management of anemia, 
including blood transfusion therapy, have been 
confounded by increased risks from anemia, along 
with additional co-morbidities. What constitutes an 
appropriate work-up for an elderly patient with 
anemia; and when to refer the patient to a 
hematologist, given the potentially large number of 
subjects involved, are significant costs-benefit 
issues.7 In this review, we summarize our approach 
for management of anemia in the elderly, with a 
focus on transfusion therapy. 
Types of anemia 
The occurrence of anaemia is due to the various red 
cell defects such as production defect (aplastic 
anaemia), maturation defect (megaloblastic anaemia), 
defects in haemoglobin synthesis (iron deficiency 
anaemia), genetic defects of haemoglobin maturation 
(thalassaemia) or due to the synthesis of abnormal 
haemoglobin (haemoglobinopathies, sickle cell 
anaemia and thalassaemia) and physical loss of red 
cells (haemolytic anaemias).8 This is a condition in 
which the body lacks the amount of red blood cells to 
keep up with the body’s demand for oxygen. 
Understanding the different classifications can help to 
recognize the symptoms and also to avoid anaemia in 
the first place.Anemia in the elderly (age>65 years) is 
defined as a hemoglobin concentration below 12 gm/dl 
in women and below 13gm/dl in men. Older persons 
with anemia suffer disability, physical decline, and 
hospitalization at higher rates than those without 
anemia.9,10 Anemia can never be considered normal in 
old age. There are 3 major classes of anemia namely 
Marrow production defects (Hypo-proliferation), Red 
cell maturation defects (Ineffective erythropoiesis) and 
Decreased redcell survival (Blood loss/ 
hemolysis).11,12 Anemia of chronic disease and 
Myelodysplastic syndromes are seen more often in 
elderly. The most common causes of anemia in the 
elderly are chronic disease and iron deficiency. 
Vitamin B12 deficiency, folate deficiency, 
gastrointestinal bleeding and myelodysplastic 
syndrome are among other causes of anemia in the 
elderly. Serum ferritin is the most useful test to 
differentiate iron deficiency anemia from anemia of 
chronic disease. The serum methyl malonicacid level 
may be useful for diagnosis of vitamin B12 
deficiency. Vitamin B12 deficiency is effectively 
treated with oral vitamin B12 supplementation. Folate 
deficiency is treated with 1 mg of folic acid daily.13 
Parameters such as serum albumin, transferrin, 
transferring saturation, cholesterol, cholinesterase, 
vitamin B12, folic acid, zinc, and absolute lymphocyte 
count are useful to assess the nutritional status.13 More 
than two thirds of anemia in the elderly can be 
attributed to two major causes, nutritional deficiencies, 
and anemia of chronic disease. As many as 33% of 
geriatric anemia’s remain unexplained and their 
pathogenesis remains speculative. Conjunctival pallor 
is a reliable sign and its presence should prompt 
clinician to order blood tests for anemia.14 As per the 
NHANES III investigators, 10% of over 5000 
community dwelling elderly subjects had anemia 
according to the WHO criteria. For the most part the 
anemia is mild, with hemoglobin levels infrequently 
less than 10 g/dL.3 Nevertheless, this mild anemia has 
been associated with significant negative outcomes, 
including decreased physical performance, increased 
number of falls, increased frailty, decreased cognition, 
increased dementia, increased hospitalization, and 
increased mortality. This group further reported that 
about one third of these anemic patients have evidence 
of a nutritional deficiency, primarily that of iron; one 
third have chronic inflammation or chronic kidney 
disease (CKD); and one third have unexplained 
anemia.3 
Pathophysiology of Geriatric anemia 
A hyperinflammatory state is typical in anemia of 
inflammation (AI), CKD, and inflamed aging. This 
state is characterized by increased hepcidin 
production in the liver, resulting in a direct negative 
impact on erythropoiesis and increased iron retention 
in the reticuloendothelial system (RES). Moreover, 
production of EPO is insufficient in response to 
anemia, and EPO response in the erythropoiesis is 
blunted. A further hallmark in the pathogenesis of AI 
is the increased phagocytosis of aging erythrocytes 
(eryptosis). Clonal disorders in leukocytes increase 
the risk of developing cardiovascular complications 
and anemia. This association may be caused by the 
promotion of inflammatory processes. Plus signs 
symbolize stimulation, and minus signs inhibition 
(Fig. 1). 
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Fig. 1. Possible mechanism of anemia in Geriatric14 
 
Diagnostic criteria 
Evaluation of geriatric anemia 
Geriatric anemia is commonly identified in patient by 
using elective surgical procedures. Anemia is a 
common condition in surgical patients and is 
independently associated with increased perioperative 
mortality. Regular approaches to evaluating a patient 
with anemia are the mean corpuscular volume (MCV) 
followed by biochemical analysis.15 The MCV has  
been shown to add value to the red cell distribution 
width (RDW) for evaluation of macrocytosis. 
However, for microcytic anemias, MCV is of less 
value, particularly for patients with iron deficiency 
who have comorbidities. However, the MCV is normal 
in 70% of patients with anemia of inflammation 
limited iron delivery to red cell precursors as indicated 
by the low transferrin saturation.16 This overlap of 
these two common causalities of anemia (iron 
deficiency and inflammation) has made the use of the 
traditional markers: MCV, transferrin saturation, and 
ferritin, difficult to interpret in routine practice. An 
algorithm for the evaluation and management of 
anemia in the elderly is presented in Fig. 2. Iron-
restricted erythropoiesis can cause anemia due to an 
absolute iron deficiency, iron sequestration which is 
mediated by hepcidin, and/or a functional iron 
deficiency due to the erythropoietin-stimulated 
erythropoiesis.17 The evaluation of anemia must also 
consider unexpected diagnoses including CKD or 
occult malignancy. If absolute iron deficiency is 
diagnosed, in the elderly postmenopausal population 
it is mandatory to rule out gastrointestinal (GI) 
pathology, including malignancy as a source of 
chronic blood loss. 
Referral to a gastroenterologist may be the most 
effective way to proceed. However, in one-third to 
two-thirds of such patients, work-up of the GI tract is 
negative. Serum creatinine and GFR must be 
determined in order to evaluate for CKD, in which 
case referral to a nephrologist may be appropriate. 
The suggested cut-off of glomerular filtration rate 
(GFR) careful history for alcohol use/abuse 
particularly in patients with an MCV > 100 may be in 
order contributing either to poor marrow reserve or 
folate deficiency in the elderly. An early study by 
Cash and Sears of 90 patients (mean age 50.9 6 16.5, 
not confined to elderly individuals) with anemia of 
chronic disease observed that there was a broader 
spectrum of associated diseases with ACD than had 
previously been recognized. A more recent study by 
Waalen et al. compared a large cohort of UAE cases 
in the elderly with a matched, non-anemic control 
group and found that IL-6 and hepcidin levels did not 
differ significantly; whereas testosterone levels were 
lower in men and erythropoietin levels were 
inappropriately low for the degree of anemia. The 
diagnosis of UAE is usually considered when other 
causes of anemia in the elderly have been eliminated. 
The diagnosis of UAE is based on the findings of a 
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hypoproliferative anemia: a low reticulocyte index 
and an inadequate erythropoietin level for the degree 
of anemia. The management of these patients is a 
serious and recurrent issue, since in the absence of an 
etiology there is no proven efficacious intervention. 
When such patients are symptomatic, when they find 
themselves in clinical situations involving blood loss, 
or when surgical intervention is required, 
consideration of transfusion therapy is necessary, as 
described below. 
 
 
      Fig 2: Evaluation & Management of Geriatric anemia18 
(Fig 2 Blurred-Please change ) 
Diagnostic aspects 
Primary laboratory evaluation in older anemic 
patients should include basic parameters including 
Hb, differential blood count, MCV, mean corpuscular 
hemoglobin, reticulocyte count, ferritin, reticulocyte 
Hb, TSAT, EPO level, CRP, fibrinogen, 
creatinine/glomerular filtration rate,vitamin B12, 
serum folate, copper, thyrotropin, lactate 
dehydrogenase, haptoglobin, alanine 
aminotransferase/aspartate aminotransferase, and 
serum electrophoresis. In quite a number of cases, 
this profile will help identify and classify nutritional 
deficiency including iron-deficient anemia, AI, and 
CKD. Depending on the clinical evaluation, more 
detailed investigations may be needed including 
gastro- and colonoscopy and ultrasound of the 
abdomen and kidney. BM aspiration and biopsy are 
mandatory to exclude hematologic disorders 
including MDS and to make an appropriate 
diagnosis, especially when additional blood count 
abnormalities or other signs of a clonal hematologic 
disease are found. These diagnostic procedures 
including BM evaluation should, however, be 
discussed in light of the burden of the procedure and 
weighed against the possible therapeutic 
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consequences of the suspected diagnosis as well as 
life expectancy and burden of anemia. The authors 
feel the patient should have a life expectancy of 
minimum 3 months in order to justify BM aspiration 
in an anemic elderly patient. 
In those with unclear results molecular, cytogenetic, 
and/or flow cytometry studies may help reach the 
conclusion that the patient is suffering from a clonal 
BM disorder such as MDS. In such studies, detection 
of clonality of myeloid cells may cause a change in 
the diagnosis, for example from ICUS to CCUS or 
even to MDS.19 There are a number of other complex 
conditions and pitfalls that may pose diagnostic 
problems in elderly patients, especially those who 
suffer from comorbidities. For example, it may be 
difficult to assess the extent of iron deficiency in 
patients suffering from inflammatory bowel disease 
and pronounced inflammatory bowel disease–related 
inflammation. In these cases, soluble transferrin 
receptor (sTfR), the sTfR/log ferritin index, and 
serum hepcidin may assist in estimating the degree of 
iron deficiency. An index above a certain cutoff level 
indicates the presence of a true iron deficiency that  
may  be  overseen  in  an  inflammatory  state  when  
using  ferritin  and  TSAT  levels  only. Specific 
cutoff levels have been published. A ratio of <1 
suggests AI, whereas a ratio of >2 suggests absolute 
iron deficiency coexisting with AI.20 Yet, it is 
important to understand that sTfR assays are not 
standardized, and therefore, a cutoff level for the 
sTfR/log ferritin index has to be established by each 
laboratory individually, depending on the sTfR 
assay.21 Other parameters like reticulocyte Hb 
content and percentage of hypochromic erythrocytes 
have proved to be informative to predict the response 
rate to iron therapy in CKD patients.22-23 
Therapeutic options 
Before establishing a treatment plan, the primary 
diagnosis and accompanying diseases with emphasis 
on treatable disorders should be properly defined. As 
mentioned before, often several causes contribute to 
anemia in the elderly. Then, optimal age-adjusted 
therapy is introduced, with recognition of potential 
side effects and impact on QoL. Even a weekly 
referral (transport burden) for injections may already 
interfere with QoL in frail patients. Whenever 
possible, the primary goal is to treat and thus 
eliminate the underlying disease and thereby the 
etiology of anemia. 
In most patients suffering from true ID, oral iron 
substitution seems to be sufficient.24 Moreover, in 
recent years new oral iron formulations like ferric 
maltol and Sucrosomial Iron showing higher 
efficacy and fewer side effects have been approved, 
thus further reducing the need for intravenous iron. 
Yet, sometimes oral application in the elderly is not 
effective because of reduced uptake in the GI tract, 
impaired compliance, and/or an inflammatory state 
leading to decreased iron utilization.25,26 In this 
situation, when oral iron does not ameliorate 
anemia, IV iron therapy may be a valuable 
alternative. Actually, a number of IV iron 
formulations are available including iron sucrose, 
ferric gluconate, and ferumoxytol. Therefore, we are 
of the opinion that IV iron supplementation should 
be recommended when oral iron preparations are 
not tolerated, in patients nonadherent to oral iron 
substitution, in case of ongoing blood loss, or if iron 
uptake in the GI tract is insufficient. 
Erythropoiesis-stimulating agents (ESAs) are so far 
registered for the treatment of anemia in CKD and in 
European Union countries in patients with MDS. 
Data on application of ESAs in other subtypes of 
anemia are limited. Nevertheless, 1 study suggested 
that EPO may be beneficial in a patient cohort of age 
65 and older African American women with no 
obvious explanation for the existing anemia.27 In that 
study, ESAs significantly increased Hb levels and 
also patients’ QoL. Yet, considering studies reporting 
a reduced EPO response in a large portion of UA 
patients, larger studies are definitely needed to 
support the idea of ESA therapy in UA patients.28 In 
general, the risk for thromboembolic complications 
increases at higher Hb levels, so that the current 
recommendation is to maintain Hb levels between 9 
and 11.5 g/dL. Blood transfusions are the first and 
most effective option for the treatment of elderly 
patients with severe, symptomatic anemia. Although 
no specific cutoff level is available for Hb, elderly 
anemic patients should always be transfused with 
recognition of comorbidities and an adequate oxygen 
supply that needs to be maintained. Transfusion 
numbers and frequency in the individual patient have 
to be based on many different factors and the overall 
situation in each case. In those with severe 
cardiovascular disorders, blood should be transfused 
more slowly and on a unit-by- unit basis, and Hb 
levels should be kept above 9 or even 10 g/dL in 
these patients. 
International Journal of Health and Clinical Research, 2020;3(3):95-100              e-ISSN: 2590-3241, p-ISSN: 2590-325X                         
                                                             
____________________________________________________________________________________________________________________________________________  
____________________________________________________________________________________________________________________________________________ 
Rastogi & Gupta           International Journal of Health and Clinical Research, 2020;3(3):95-100 
www.ijhcr.com                              
                    100 
  
Thanks to a better understanding of mechanisms 
regulating erythropoiesis, new drugs are currently 
being developed such as hepcidin inhibitors (Table 
4). Currently, these drugs are mainly developed for 
anemia in CKD and cancer patients. However, they 
may be a future therapeutic approach for a defined 
group of elderly patients. Another group of agents are 
the hypoxia inducible factor (HIF)–prolyl 
hydroxylase inhibitors. Especially older patients with 
low endogenous EPO levels may benefit from these 
drugs. Yet, persons at advanced age may be more 
vulnerable to HIF stabilization. Finally, activin type 
II receptor agonists are currently being investigated 
in patients with MDS and CKD and might present a 
future option for the treatment of anemia at advanced 
age. As sufficient clinical data are not yet available, 
these drugs still await final approval. 
Conclusion 
Anemia in the elderly (defined as people aged > 65 
years) is common and increasing as the population 
ages. In older patients, anemia of any degree 
contributes significantly to morbidity and mortality 
and has a significant effect on the quality of life. 
Despite its clinical importance, anemia in the elderly 
is under-recognized and evidence-based guidelines 
on its management are lacking. In this review we 
support the notion that Each patient must be 
evaluated individually, and patient-specific anaemia 
management strategies be employed. 
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